221 related articles for article (PubMed ID: 28289863)
1. A phase II study of REOLYSIN
Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J
Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
3. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C; Kuruvilla S; Keith BD; Torri V; Blais N; Hao D; Korpanty GJ; Goss G; Melosky BL; Mates M; Leighl N; Ayoub JP; Sederias J; Feilotter H; Seymour L; Laurie SA
Lung Cancer; 2018 Jun; 120():142-148. PubMed ID: 29748010
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
Noonan AM; Farren MR; Geyer SM; Huang Y; Tahiri S; Ahn D; Mikhail S; Ciombor KK; Pant S; Aparo S; Sexton J; Marshall JL; Mace TA; Wu CS; El-Rayes B; Timmers CD; Zwiebel J; Lesinski GB; Villalona-Calero MA; Bekaii-Saab TS
Mol Ther; 2016 Jun; 24(6):1150-1158. PubMed ID: 27039845
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.
Jonker DJ; Tang PA; Kennecke H; Welch SA; Cripps MC; Asmis T; Chalchal H; Tomiak A; Lim H; Ko YJ; Chen EX; Alcindor T; Goffin JR; Korpanty GJ; Feilotter H; Tsao MS; Theis A; Tu D; Seymour L
Clin Colorectal Cancer; 2018 Sep; 17(3):231-239.e7. PubMed ID: 29653857
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Pelareorep (REOLYSIN
Mahalingam D; Goel S; Aparo S; Patel Arora S; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Gutierrez A; Coffey M; Nawrocki ST; Nuovo G; Mita MM
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29799479
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
Bernstein V; Ellard SL; Dent SF; Tu D; Mates M; Dhesy-Thind SK; Panasci L; Gelmon KA; Salim M; Song X; Clemons M; Ksienski D; Verma S; Simmons C; Lui H; Chi K; Feilotter H; Hagerman LJ; Seymour L
Breast Cancer Res Treat; 2018 Jan; 167(2):485-493. PubMed ID: 29027598
[TBL] [Abstract][Full Text] [Related]
9. NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
McWilliams RR; Allred JB; Slostad JA; Katipamula R; Dronca RS; Rumilla KM; Erickson LA; Bryce AH; Joseph RW; Kottschade LA; King DM; Leitch JM; Markovic SN
Cancer; 2018 Feb; 124(3):537-545. PubMed ID: 29044496
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
Black AJ; Morris DG
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):517-20. PubMed ID: 23121273
[TBL] [Abstract][Full Text] [Related]
11. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
12. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Lee CK; Jung M; Choi HJ; Kim HR; Kim HS; Roh MR; Ahn JB; Chung HC; Heo SJ; Rha SY; Shin SJ
Cancer Res Treat; 2015 Oct; 47(4):781-9. PubMed ID: 25687848
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
14. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Croghan GA; Suman VJ; Maples WJ; Albertini M; Linette G; Flaherty L; Eckardt J; Ma C; Markovic SN; Erlichman C
Cancer; 2010 Jul; 116(14):3463-8. PubMed ID: 20564112
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
Kottschade LA; Suman VJ; Amatruda T; McWilliams RR; Mattar BI; Nikcevich DA; Behrens R; Fitch TR; Jaslowski AJ; Markovic SN
Cancer; 2011 Apr; 117(8):1704-10. PubMed ID: 21472717
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
[TBL] [Abstract][Full Text] [Related]
17. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
20. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
Hauke RJ; Infante JR; Rubin MS; Shih KC; Arrowsmith ER; Hainsworth JD
Melanoma Res; 2013 Dec; 23(6):468-73. PubMed ID: 23969699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
